February 2025's Leading Growth Stocks With Insider Influence

As global markets grapple with tariff uncertainties and mixed economic signals, investors are keenly observing growth companies that demonstrate resilience and potential. In this environment, stocks with high insider ownership can be particularly appealing, as they often indicate a strong alignment of interests between company leaders and shareholders.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
Duc Giang Chemicals Group (HOSE:DGC)	31.4%	25.7%
Seojin SystemLtd (KOSDAQ:A178320)	32.1%	39.9%
Clinuvel Pharmaceuticals (ASX:CUV)	10.4%	26.2%
Laopu Gold (SEHK:6181)	36.4%	36.9%
Medley (TSE:4480)	34.1%	27.3%
Plenti Group (ASX:PLT)	12.7%	120.1%
Fine M-TecLTD (KOSDAQ:A441270)	17.1%	135%
HANA Micron (KOSDAQ:A067310)	18.3%	119.4%
Fulin Precision (SZSE:300432)	13.6%	71%
Findi (ASX:FND)	35.8%	111.4%

Click here to see the full list of 1439 stocks from our Fast Growing Companies With High Insider Ownership screener.

We'll examine a selection from our screener results.

Chifeng Jilong Gold MiningLtd (SHSE:600988)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Chifeng Jilong Gold Mining Co., Ltd. is a company engaged in the mining of gold and non-ferrous metals, with a market capitalization of CN¥32.63 billion.

Operations: Chifeng Jilong Gold Mining Co., Ltd. generates revenue primarily through its operations in gold and non-ferrous metal mining.

Insider Ownership: 16.1%

Revenue Growth Forecast: 14.9% p.a.

Chifeng Jilong Gold Mining Ltd. is trading at a substantial discount to its estimated fair value and shows promising growth prospects, with earnings having grown significantly by 141.7% over the past year. Analysts forecast continued earnings growth of 21.86% annually, although this is below the market average in China. Despite recent removal from major indices like SSE 180, upcoming shareholder meetings indicate active management involvement in strategic planning and employee incentives, highlighting strong insider engagement.

• Dive into the specifics of Chifeng Jilong Gold MiningLtd here with our thorough growth forecast report.
• In light of our recent valuation report, it seems possible that Chifeng Jilong Gold MiningLtd is trading behind its estimated value.

DBAPPSecurity (SHSE:688023)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: DBAPPSecurity Co., Ltd. focuses on the research, development, manufacture, and sale of cybersecurity products in China with a market cap of CN¥8.20 billion.

Operations: The company's revenue segments include cybersecurity product sales and related services in China.

Insider Ownership: 13%

Revenue Growth Forecast: 19% p.a.

DBAPPSecurity is trading at a significant discount to its estimated fair value, indicating potential undervaluation. Analysts expect revenue to grow 19% annually, outpacing the broader Chinese market. Despite recent exclusion from the S&P Global BMI Index and high share price volatility, forecasts suggest profitability within three years with substantial earnings growth of 53.76% per year. The upcoming shareholder meeting underscores active management engagement amid stable insider ownership levels without recent trading activity.

• Navigate through the intricacies of DBAPPSecurity with our comprehensive analyst estimates report here.
• The analysis detailed in our DBAPPSecurity valuation report hints at an deflated share price compared to its estimated value.

Caliway Biopharmaceuticals (TWSE:6919)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Caliway Biopharmaceuticals Co. Ltd specializes in developing small molecule drugs for medical aesthetics and inflammatory diseases, with a market cap of NT$137.17 billion.

Operations: The company generates revenue of NT$49.98 million from its pharmaceuticals segment.

Insider Ownership: 24.4%

Revenue Growth Forecast: 120.3% p.a.

Caliway Biopharmaceuticals is trading significantly below its estimated fair value, with revenue projected to grow at a very high rate of 120.3% annually, surpassing the broader Taiwan market. Despite lacking meaningful current revenue and experiencing share price volatility, Caliway's recent successful Phase 2b trial for CBL-514 highlights strong efficacy in non-surgical fat reduction. The company plans a pivotal Phase 3 trial in late 2025, aiming for profitability within three years while maintaining stable insider ownership levels without recent trading activity.

• Click here to discover the nuances of Caliway Biopharmaceuticals with our detailed analytical future growth report.
• Our valuation report unveils the possibility Caliway Biopharmaceuticals' shares may be trading at a premium.

Make It Happen

• Click through to start exploring the rest of the 1436 Fast Growing Companies With High Insider Ownership now.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com